Subject Index

A

Absorption—airways gas transport, 115–117, 121
Absorption efficiency, 119, 210(fig), 121(table)
Acid aerosols
  and asthma, 207–213
  sensitivity, 49
Adaptive immune system, 33, 34
Adolescent subjects, 207
Adverse health effects of ambient air pollutants, 6–8
Aerosol bolus technique, 97, 127–138
Aerosol boluses
  diagnostic use, 137
  dispersion in exhaled air, 130–131(figs)
  dispersion in patients with asthma or emphysema, 132(fig)
  inhalation apparatus for lung studies, 128(fig)
  technique, 127
Aerosols
  airway hyperresponsiveness, 50
  and asthma—adolescent subjects
    after exercise-induced bronchospasm, 208
    forced expiratory volume (FEV), 210(fig)
    methods of study, 208–209
    physical characteristics of subjects, 209(table)
    pulmonary function values, 210(table)
    results, 209
Age factors
  relationships between human and animal ages, 151
  sensitivity to hyperoxia in animals, 24
  susceptibility to inhaled pollutants, 148
Aged populations
  affected of increases in pollutant levels, 149
Air pollution
  acute respiratory responses, 75
  adverse health effects, 7–20
  asthma, 68
  chronic respiratory illness, 174
  epidemiologic studies, 7–20, 184
  health effects, 8–9, 49, 57
  individual response—variability, 76
  inhaled chemicals, 100–110
  oxidants and bacterial infections, 184
  standards development, 6–20
  study group responses, 55, 57
  susceptible populations, 3–4, 6–20, 141
Air pollution episodes, 3–5
Air pollution exposure,
  asthmatic subjects—selection for study, 61(table)
Air quality guidelines
  World Health Organization, 110
Airborne gaseous contaminants—upper respiratory tract
  airflow through different airways, 102–103
  chemical and physical properties, 100
  effects of ventilation parameters, 101(fig)
  scrubbing, 105
Airflow patterns through the human head, 101(fig)
Airway anatomy, 113
Airway charting
  tracheobronchial tract, 132
Airway gas transport, 115, 116(fig), 117(table)
Airway hyperreactivity/reactivity
  allergens, 39
  asthma, 49
  inhaled chemicals, 39
  nitrogen dioxide and asthma, 218–223
  ozone exposure, 188
  respiratory tract infections, 39
Airway hyperresponsiveness, 49–52
Airway inflammation, 52
Airway resistance, 103(fig), 130(table), 195
Airway responsiveness—asthma *See also* Airway hyperresponsiveness
  epidemiological studies, 68–74
Airway scrubbing, 100–110

Airway smooth muscle
  mechanisms for minimizing contraction, 50(fig), 51(tables)
Airway transport model, 124
Allergy, 141, 144
Alveolar macrophage (AM)
  cells in lavage fluids, 36
  function in animals, 187
  principal phagocytic cell in airways, 35
Alveolar ventilation, diffusion and perfusion, 118(fig), 120
Ambient air pollutants
  physiological response, 76–77
  susceptible populations, 6–19
Ambient air standards, 6–19
Agina pectoris
  adverse effects
    ambient air pollutants, 9–11
    of carbon monoxide exposure, 10
Animal studies—literature review, 149, 150(table)
Antimicrobial defense of lower respiratory tract, 187
Asbestos fibers
  tissue injury in animals caused by inhalation of particulates, 28(fig), 30
Asthma
  acid aerosols, 207–213
  aerosol boluses, 132
  air pollution exposure, 61(table), 68
  airways responsiveness, 4, 49–55, 58
  and wheeze, 143
  clinical and epidemiological studies, 57–67
  environmental pollution conditions, 219–220
  epidemiology, 57–67, 219
  identification of susceptible populations, 56, 57
  in children, 143, 144
  mechanisms of susceptibility, 40–41
  nitrogen dioxide exposure, 60(table), 218–220, 221(table)
  nonuniformity of ventilation distribution, 55
  occupational, 38–39, 40(table)
  ozone effects, 56
  ozone or oxidant exposure, 60(table)
  population surveys, 62(table)
  role of immune cells and mediators in pathogenesis, 39
  sensitivity, 49
  sulfur dioxide-induced bronchoconstriction, 195
  susceptibility, 58
  sulfur dioxide exposure, 59(table)
Asthmatics
  air pollution exposure, 55–56, 61(table), 57–67
  airway responsiveness
    inhaled antigen, 216
    nitrogen dioxide, 218
    ozone, 215
    sulfur dioxide exposure, 59(table)
    sulfur dioxide inhalation in exercise and resting, 196, 198
  exercise, 198
  forced expiratory volume, 62(table)
  health effects of sulfuric acid inhalation, 207
  sulfur-dioxide exposure, 59(table)

B

Bacterial infections—oxidants, 184
BAL. *See* Bronchoalveolar lavage.
BALF. *See* Bronchoalveolar lavage fluid.
Biological markers. *See* Immunological markers
Blood flow patterns during exercise, 113(table), 115
Bohr model—gas transport, 117
Breathing pattern variations
  climatological factors, 102–103
  exercise, 104
  oronasal breathing, 102–104
Bronchial circulation, 115
Bronchial hyperreactivity
  general population, 144
Bronchial responsiveness of asthmatic subjects
  epidemiological studies, 68–69
Bronchiolitis, 55
Bronchitis
  early childhood, 143
Bronchoalveolar lavage (BAL), 35, 188
  fluid (BALF)
Bronchoconstriction in asthmatics
  sulfur dioxide exposure, 195–199
Bronchoconstrictor effects of air pollutants, 52
Bronchoconstrictor stimuli, 50
Bronchospasm, exercise induced, 208

C

Carbon monoxide exposure
  Criteria Documents for CO exposure
    EPA-600/8-79-011, 9
    EPA-600/8-83-033F, 10

EPA-450/5-84-004
45FR 55066 (Federal Register, August 1980), 10
health effects, 6–19
susceptible populations, 4, 6
Carboxyhemoglobin
biological dose indicator for carbon monoxide, 100
carbon monoxide reaction with hemoglobin, 8
Cardiovascular patients
adverse effects
of ambient air pollutants, 9–11
of carbon monoxide exposure, 10
CASAC. *See* Clean Air Scientific Advisory Committee
Cell injuries in animal lungs
from breathing oxidant gases or inhaling particulates, 27(fig)
Charting human airways, 127
Chemiluminescent detector
determinations of nitrogen dioxide concentrations, 105
Chemotaxis, 34
Childhood, early
lower respiratory illness, 142
Children
susceptibility to chemicals, 3
Chronic obstructive airways diseases, 141–147
Chronic obstructive pulmonary disease (COPD),
air quality criteria document, 175
risk factors, 175(table)
Chronic respiratory disease
pathogenesis, 227, 228(fig)
Circulation—blood flow, 115
Clean Air Act (CAA) of 1970. *See* Standards
Clean Air Scientific Advisory Committee (CASAC), 6–19
Clearance, 127
Climatological factors in breathing patterns, 103
Clinical and epidemiological studies
subject selection, 64–65
COPD. *See* Chronic obstructive pulmonary disease
Criteria pollutants, 6–7
Cystic fibrosis, 55

D

Defense mechanisms
animal response to oxidant exposures, 30(fig)
Deficiencies of nutritional components affect lung size, structure and function, 170
Deposition of insoluble particles in human subjects, 92
Dermatophagoides pteronyssinus (house dust mite), 39
Diagnostic methods for study of human lungs, 127
Diffusion, alveolar, 118(fig)
Diffusion limited behavior absorption efficiency, 119, 120(fig)
Diffusion, pulmonary, 111, 116, 117(fig)
Diffusion resistance, 116, 117(table)
Disease
individual predisposition, 3
mechanisms of inhaled pollutants, 224
Dispersion—aerosol bolus, 127–131(figs)
Dose-response
inhaled pollutants, 224
Dosimetry
biological indicators of dose carboxyhemoglobin in blood as measure of carbon monoxide exposure, 100
exercise factors, 91–99, 111–126
lungs, 100–110
respiratory tract susceptibility to inhaled gases and particles, 91–99
mathematical models, 97

E

Elastin metabolism (lung elastin)
animal studies, 166–167
Emission standards
for hazardous pollutants, 7
Emissions
respiratory effects of indoor air pollutants, 40
Emphysema
aerosol boluses, 132
variations in gas distribution, 55–56
Emphysema-like lesions
nitrogen dioxide exposure, 12
Environmental exposure to inhaled pollutants, 230
Environmental exposure chambers, 76
Environmental pollutants
effects of inhalation into tracheobronchial tree, 113
immunological markers of susceptibility, 33
safety standards for exposure, 23
tobacco smoke—passive exposure in childhood, 146

Environmental Protection Agency (EPA)
See also Standards
Clean Air Act, 6–19
Epidemiologic studies
air pollution, 8–14, 184
airways responsiveness, 68–72
animal infective models, 185
asthmatics, 57–67
methodology, 57–67, 72
Epithelium
possible barrier to bronchoconstrictors, 50
Exercise
airflow patterns in upper respiratory tract, 101(fig)
airway concentrations—response, 124–125
asthmatics, 190
effect on distribution of ozone dose, 123(fig)
effect of turbulance in airways, 114(fig)
experimental regimen for gases and particles, 91
influence on regional respiratory tract dosimetry, 92–93
regional dosimetry, 96, 97(fig), 110, 111–126
upper airway scrubbing, 100
Exercise-induced bronchospasm, 208
Experatory volume, forced. *See* Forced expiratory volume (FEV)
Experimental design for clinical and epidemiological studies of asthma, 57
Expired aerosol boluses—dispersion, 129
Exposure-dose response relationships
inhaled pollutants, 4–5, 229, 230(fig)
Exposure duration
asthmatics exposed to sulfur dioxide, 199–200
Exposure temperature/humidity
bronchoconstriction in asthmatics exposed to sulfur dioxide, 200–202

F

Feedback mechanisms
in immune system, 34
Fetus, 3–4
Fiberoptic bronchoscopy
in diagnosis of lung disease, 35, 188
Forced expiratory volume (FEV)
asthmatics, 62–64(figs), 69(fig), 210(fig)

G

Gas stoves
source of nitrogen dioxide, 219
Gas transport in airways
exercise and regional dosimetry, 111–126
Gas uptake from respiratory zone, 118(fig)
Gaseous contaminants—airborne, 100

H

Hazardous air pollutants
adverse health effects, 7
Clean Air Act of 1970
Section 109(b) (1), 7
Section 112, 8
national emission standards, 7
Health effects of air pollution, 6—19, 49, 57–58
Host factors
asthma studies, 57
House dust mite
may induce airway hyperreactivity, 39
Human alveolar macrophage, 188
Human exposure research, 13–14, 91
Human exposure to oxidants, 188
Human immunodeficiency virus, 187
Human respiratory infection
ozone may increase susceptibility to experimental bacterial infection, 185
Human respiratory tract
aerosol boluses for diagnostic purposes, 137
ozone irritation, 174
Hygroscopic particles
respiratory tract deposition, 91, 94, 95(table)
Hyperoxia
acute lung injury, 23
animal studies, 23–31
age sensitivity, 24
effects of lethal and sublethal levels in animals, 24, 25(figs)
enhanced oxygen tolerance in younger animals, 163
Hyperreactivity in the lung, 41, 43
Hyperresponsive airways, 207
Hyperresponsiveness, 42, 51(tables)
Hypersensitivity pneumonitis, 38, 39(tables), 40(table)

I

Immune response
  reaction to infectious agents, 33
Immune system
  control mechanisms, 33–34, 42
Immunologic lung disease. *See* Lung disease
Immunological markers of susceptibility
  chemicals associated with work environment, 38, 39(tables)
  hypersensitivity pneumonitis, 38, 39(table)
  modulation and detection, 35–37
  of sarcoid in BAL, 37(table)
  prediction of susceptibility to inhaled pollutants, 32–46
  questions, 34–35
  respiratory tract dosimetry, 91–99
  response of laboratory animals, 149
  response to environmental stimuli, 34
  susceptibility—age and aging in animals, 157–159
  susceptibility of immature animals, 153–157
  susceptibility of maturing animals, 158–159
  susceptible individuals, 224–231
Inflammation
  airway responsiveness, 49–54
  markers, 34, 41
  reaction to injury, 33
Inflammatory lung disease. *See* Lung disease.
Inhalation technique
  for study of human lung characteristics, 127
  radioactively labelled particles for smokers and nonsmokers
    clearance curve, 135
Inhalation toxicology
  airway branching patterns, 30
  animal studies, 23, 29, 30
  asthma and nitrogen dioxide, 218–222
  tissue injury, 30
Inhaled pollutants and toxicants
  age factors, 148
  chemicals, 100–110
  clinical and epidemiological studies of asthma, 63(figs)
  deposition in larynx, 98
  deposition in lung, 106–107
  dose-response, 224
  gas pollutants and genetic control, 41
  immunological markers, 32–46
  particles, 91–99
  present standards reflect young-to-mid-aged adult population, 148
  respiratory tract dosimetry, 91–99
  response of laboratory animals, 149
  susceptibility of aged animals, 159
  susceptibility of aging animals
    to nitrogen dioxide, 157–158
    to synthetic smog, 158
  susceptibility of immature animals
    cigarette smoke, 157
    diesel exhaust, 156–157
    nitrogen dioxide, 153–154
    oxygen, 156
    ozone, 154–156
    sulfur dioxide, 156
  susceptibility of maturing animals, 158–159
    susceptible individuals, 32, 37
Innate immune system, 33
Insoluble particles
  respiratory tract deposition in humans, 91–99
Interstitual lung disease. *See also* Lung disease.
  inherited
    familial idiopathic pulmonary fibrosis, 42
    pulmonary sarcoidosis, 42
  role of genetic factors, 42
Isocyanate
  immunologic testing of exposed workers, 42

L

Lead *See also* Standards susceptible populations, 4, 7, 10–11
Lower airways, 111
Lower respiratory illness
  in early childhood, 142
  respiratory syncytial virus, 142
Lung antioxidant defenses, 162
Lung disease, obstructive, inflammatory and interstitial
  bronchiolitis, 55
  fiberoptic bronchoscopy, 36
  immunopathogenesis, 36
  individual variability—response to ozone exposure, 86
  susceptible populations identification, 55
  ventilation distribution, 55
Lung disorders, 32

Lung dosimetry
lower airways gas transport, 111–126
upper airway scrubbing, 100–110
Lung elastin—metabolism
animal studies, 166–167
Lung function
affected by severe nutritional deficiencies, 170
age factors, 148
design of clinical laboratory studies, 180
in children, 142–145
inhalation exposures to pollutants affected by age, 149
Lung function studies, 16, 41
Lung injury
animal studies of sensitivity to pollutants, 23–31
caused by oxidant gases, 26, 27(figs), 29(figs)
chronic damage from inhaled chemicals, 100
morphologic changes during exposure to hyperoxia, 25–26(figs)
nonuniformity of ventilation distribution in asthmatics, 55
response to exercise, 111
Lung mass transfer coefficients, 111–126
Lung studies–aerosol boluses, 127–138
Lung tissue damage
nitrogen dioxide exposure, 12
Lungs, human
aging during adulthood, 152
antioxidant defense mechanisms, 162
growth from birth to adulthood compared to laboratory animals, 151
study of characteristics, 127
susceptibility to inhaled pollutants, 151–152

M

Mass transfer coefficients, lung, 111, 116(fig)
Mathematical modeling
airway transport model, 124(fig)
Bohr model, 117, 122, 123(fig)
exercise and dosimetry, 122–123
transport of insoluble gases, 123
Mechanisms of predisposition to disease
inhaled pollutants, 3
metabolism, 3
vulnerability, 3
Metabolism
mechanisms for predisposition to disease, 3
Modelling response
to identify responsive individuals, 79
Mucociliary transport
adversely affected by exposure to oxidants, 186

N

NAAQS. *See* National Ambient Air Quality Standards
Nasal airway resistance and airflow, 103(fig)
Nasal breathing, 102
National Ambient Air Quality Standards (NAAQS), 6, 227
See also Standards
National Emission Standards for Hazardous Air Pollutants (NESHAP), 7
See also Standards
NESHAP. *See* National Emission Standards for Hazardous Air Pollutants
Nitrogen dioxide *See also* Standards
air quality standards, 12–13
altered lung function, 12
asthmatic subjects–selection for clinical studies, 60(table)
effect on airway responsiveness in asthmatics, 52, 68
emphysema-like lesions, 12
epidemiology and asthma, 219–220, 221(table), 222
exercise and dosimetry, 91
exercise-related ventilatory changes, 108, 109(table)
experimental measurement of upper respiratory tract scrubbing in test animals, 105, 106(fig)
exposure, 13, 37–38
lower respiratory tract (lung), 107
pulmonary effects in asthmatics, 221(table)
resistance, 38
susceptible populations, 7, 10–11
treatment with vitamin C, 222
uptake in head and lungs of dogs, 108(fig), 109(table)
Nonspecific immune system, 33
Nutrition
amino acid deficiencies, 162
antioxidant defense mechanisms
copper, 162
selenium, 162
vitamin C, 163

vitamin E, 162
zinc, 162

O

Obstructive lung disease. *See* Lung disease.
Occupational asthma, 39, 40(table)
Occupational exposures
inhaled pollutants, 32–46
Oral breathing, 102
Oronasal breathing, 100
Oxidant effects on macrophage-virus interaction, 187
Oxidant exposure *See also* Ozone
linked to susceptibility to infection, 189
relationship to chronic obstructive pulmonary disease, 174–175
relationship to respiratory infection, 182
Oxidant gas
exercise and dosimetry, 96, 97(fig)
lung injury, 26–27
See also Ozone
Oxidant injury
lower respiratory tract, 23–26
Oxidant pollutants
modulation of immunological markers, 37
Oxidants
bacterial infections, 184
exercise and regional dosimetry, 91–99
potential cocarcinogens or promoters, 169–170
viral infections—animal infectivity models, 185
Oxygen
animal studies
effects of low protein diet, 164
sensitivity to lung injury, 23–31
mortality of exposure, 25(fig)
toxicity—animal studies, 163
Ozone or oxidant exposure *See also* Oxidant exposure, Standards
air quality standards, 6–20
animal studies on sensitivity, 27–28(figs)
exercise and dosimetry, 91
airway responsiveness, 49–54
asthmatic subjects—selection for clinical studies, 60(table)
epidemiologic studies, 214
experimental design for studies, 179
human exposure health effects, 14
human health consequences, 174
human lung uptake, 96, 97(fig)
in asthmatics, 214–215
individual respiratory responses, 75, 82–84
individual variability, 84–85
injury from inhaled oxidants, 183
lung function responses, 178–179(figs)
population studies, 183
reactivity laboratory study—design, 177
respiratory effects, 85
risk assessment studies—design, 180(tables)
susceptibility to inhaled pollutants, 224
susceptible populations, 6, 13–14, 23

P

Particle concentration monitoring
aerosol bolus, 128(fig), 129(fig)
Particle recovery from respiratory tract 133(fig)
Particulate matter
criteria documents, 6
deposition data, 93
exposures, 16–18
thoracic deposition, 93
tracheobronchial deposition, 93(fig)
Passive tobacco smoke
relationship to lung function in childhood, 144
Perfusion
absorption efficiency, 120(fig), 121(table)
Perfusion, alveolar, 118, 120
Perfusion-limited behavior
absorption efficiency, 119, 120(fig)
Perfusion, pulmonary, 111–126
Permeability, markers, 34
Phagocytosis
defense mechanism of lung against infection, 35
measurement, 43
respiratory infection and oxidants, 187
Photochemical oxidants. *See* Ozone
Pneumonitis, hypersensitivity
work environment organic dusts, 38, 39(table)
Pollutant gas dosimetry, 124–125
Pollutants
ambient air, 6
environmental
immunological markers of susceptibility, 33
safety standards, 22

Pollutants (*cont.*)
exposure, 111–126
inhalation—individual responsiveness, 203
oxides of nitrogen, 3
ozone, 3
Polymorphonuclear neutrophils (PMN), 33, 36
Predisposition
to disease, 3
Protein-calorie deficiencies
animal studies, 165–166
Pulmonary circulation, 115, 118
Pulmonary condition defects, 55
Pulmonary diffusion, 111–126
Pulmonary effects of nitrogen dioxide in asthmatics, 221(table)
Pulmonary fibrosis, 42
Pulmonary function
changes in asthmatic adolescents after inhaling sulfuric acid, 207, 210–212
ozone exposure, 75–88
Pulmonary immune system, 36
Pulmonary perfusion, 111–126
Pulmonary responses of asthmatics
sulfur dioxide-induced bronchoconstriction, 196–197
Pulmonary sarcoidosis, 42
Pulmonary uptake during exercise, 119
Pulmonary ventilation
perfusion ratio, 111–126

R

Radioisotope measurements, 120
Reactivity to ozone—laboratory study, 177
Reproducibility
of individual responses, 81
of oronasal switching point
Respiration during exericse, 112–115
Respiratory health
childhood factors related to adulthood, 141–147
Respiratory infections
and oxidants, 182
in children, 141–147
relationship to chronic obstructive pulmonary disease, 174
susceptible population models, 141–147
Respiratory response—individual to ozone exposure, 75–76, 85
Respiratory symptoms, 195
Respiratory syncytial virus in early childhood, 142
Respiratory system
inhaled pollutants, 148
Respiratory tract
deposition of insoluble particles, 92
dosimetry of inhaled particles, 91–99
exercise and dosimetry, 91–99
infection may induce airway hyperreactivity, 39
particle dose, 95
susceptible individuals, 3
tracheobronchial and thoracic deposition curves, 93–94(figs), 95(table)
Respiratory virus challenge
defense mechanisms, 185–186
lung function review, 141–147
specific effects of oxidants, 186
Review—lung function, 141–147
Risk assessment, 43
Risk factor relationships—chronic respiratory illness
design of studies, 176(table)

S

Safety margin for air pollution, 7–20
Sarcoidosis
immunological control mechanisms impaired, 36, 37(table)
pulmonary—inherited, 42
Selenium deficiency
enhanced toxicity of ozone, 163
rats more susceptible to hyperoxia, 163
Sensitivity to acid aerosols, 49
Sick building syndrome, 40
Smokers and nonsmokers
aerosol bolus inhalation—lung studies, 135, 136(fig, table)
Smokers' lungs, 33, 35–37
Smokers' response to ozone exposure, 85
Smoking
relation to chronic obstructive pulmonary disease, 174
Smoking by children
relationship to rate of growth, 144–145
SOD. *See* Superoxide dismutase
Species sensitivity
to lung injury, 23–31
to oxidant gases, 27
Specific immune system, 33, 34

Spirometry, 180
Standards
 air quality guidelines, World Health Organization, 9
 ambient air pollutants, 6–20
 EPA Clear Air Act of 1970
  Co Criteria document
   EPA-600/8-79-011, 9
   EPA-600/8-83-033F, 10
   EPA-450/5-84-004, 10
   Federal Register:
    44 FR 8207, (Oct. 1979), 9
    45 FR 55066, (Aug. 18, 1980), 10
  Lead Criteria documents
   Federal Register:
    43 FR 46246, (Oct. 5, 1978), 10
  Ozone Criteria documents
   EPA-600/8-84-020 (Aug. 1986), 14
   36 FR 8186 (Apr. 30, 1971), 13
   44 FR 8202 (Feb. 1979), 13
 Particulate matter, Criteria Documents, NAAQS:
   36 FR 8186 (Apr. 30, 1971), 15
   49 FR 10408 (Mar. 20, 1984), 15
   EPA-600/8-82-029 (1982), 15
   EPA-450/5-82-007 (1982), 15
   EPA-CASAC-87-101 (1986 addendum), 16
    London mortality studies, 16
    particle size indicators (Jan. 29, 1982 reaffirmed), 16
Standards development, 6–20
Statistical methods
 individual variability, 78–79
Sulfur dioxide
 See also Standards
 exposure
  asthmatic subjects—selection for clinical studies, 59(table), 68
  bronchoconstriction in asthmatics, 195, 197, 204
  exercise and dosimetry, 91
 responsiveness
  variability in asthmatic population, 202–203, 207
Sulfuric acid effects
 asthma, 68
 exercise and dosimetry, 91
 health effects in asthmatics, 207
Superoxide dismutase (SOD)
 pulmonary activity in different species, 24(table)
Susceptibility
 immunological markers, 32–46
 overview, 3–6
Susceptible populations to air pollution
 age factors, 148–161
 air pollution, 3–4, 6–20, 141
 animals, 23–31
 asthma, 55, 227
 bronchoconstrictor effects, 52
 children, 3
 effects of indoor air pollutants, 40
 effects of inhaled pollutants, 148, 225, 226(fig)
 identification, 6, 56
 immunological markers, 32–46
 inhaled pollutants, 43
 mechanisms, 41
 responses, 6–19
 standards, 6–19

T

Tachykinins
 effect on airway smooth muscle, 50
Thoracic deposition of insoluble particles, 92–93, 94(fig)
Tissue injury in animals
 caused by inhalation of particulates, 30
Tobacco smoke exposure in childhood, 146
Toxicology, susceptibility to inhaled pollutants, 148
Tracheobronchial tract
 aerosol boluses—technique for diagnostic studies, 137
 charting, 137
 deposition of particles, 93–94(figs), 95(table)
 particle charting of airways, 134

U

Upper respiratory tract
 efficiency of particle removal during rest and exercise, 98
 upper airway scrubbing, 101, 105
Uptake, *See* Absorption.

V

Variability
 acute physiological response among individuals exposed to comparable inhaled doses of ozone, 76–83

Variability (*cont.*)
in individual response and susceptibility, 3–4, 76
methods for measurement of individual response, 77–78
ozone responsiveness, 82–86
Ventilation, alveolar, 118
Ventilation and blood flow, during exercise 113(table), 120
Ventilation distribution, nonuniformity, in asthmatics, 55
Ventilation factors
bolus technique, 137
exercise related, 106–108, 109(table)
exposure duration, 199
gas transport, 118, 124–125
patterns during exercise, 113(table)
Ventilation-perfusion ratio, absorption efficiency, 119, 120(fig)
Ventilation, pulmonary, 111–126
Viral respiratory infections
in lower levels of small airway function, 145
Vitamin B-6 deficiency
animal studies, 166
Vitamin C
in synthesis of collagen and elastin, 167
inhibits airway reactivity following exposure to nitrogen dioxide, 222
Vitamin E
deficiency enhanced toxicity of ozone, 163
ratio of polyunsaturated fatty acids, 169
Vulnerability
mechanism for predisposition to disease, 3

W

Wheezing. *See* Asthma, Bronchitis
World Health Organization—European Region air quality guidelines, 9